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Non-communicable diseases, the major global 
health problem of the century
Chronic  diseases  are  disorders  of  long  duration  and 
generally slow progression [1]. They include four major 
non-communicable diseases (NCDs) listed by the World 
Health  Organization  (WHO)  [2]  –  cardiovascular 
diseases,  cancer,  chronic  respiratory  diseases  and 
diabetes  –  as  well  as  other  NCDs,  such  as 
neuropsychiatric disorders [3] and arthritis. As survival 
rates have improved for infectious and genetic diseases, 
chronic  diseases  have  come  to  include  communicable 
diseases (such as HIV/AIDS) and genetic disorders (such 
as  cystic  fibrosis).  NCDs  represent  the  major  global 
health problem of the 21st century [4,5]; they affect all 
age groups [6] and their burden is greater than that of 
infectious diseases. NCDs are the world leading cause of 
disease burden and mortality [2] and are increasing in 
prevalence  and  burden  [7],  even  in  low-  and  middle-
income  countries  [8].  Costs  incurred  by  uncontrolled 
NCDs  are  substantial,  especially  in  underserved 
populations [9] and low- and middle-income countries 
[10,11]. NCDs are an under-appreciated cause of poverty 
and  hinder  economic  development  [11].  Importantly, 
management  of  NCDs  has  recently  been  prioritized 
globally (Box 1).
Chronic  diseases  are  caused  by  complex  gene-
environment interactions acting across the lifespan from 
the  fetus  to  old  age  (Figure  1).  In  this  context, 
‘environment’  includes  risk  and  protective  factors 
associated  with  environment  and  lifestyle,  such  as 
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sedentary life [2].
Socio-economic determinants are intertwined with the 
onset, progression, severity and control of NCDs. There 
are  functional  interdependencies  between  molecular 
components,  reflecting  complex  network  perturbations 
that link cells, tissues and organs [12]. Early life events 
are  crucial  in  the  generation  of  NCDs,  and  aging 
increases disease complexity, adding, for example, tissue 
and cell senescence [13]. Comorbidity refers to the co-
existence of two or more diseases or conditions in the 
same  individual  that  have  similar  risk  factors  and/or 
mechanisms. Most people with NCDs suffer from two or 
more  diseases  [14].  Co-morbidity  and  multi-morbidity 
are common signatures of NCDs and are associated with 
worse  health  outcomes  [15],  complex  pharmacological 
interventions  and  clinical  management,  and  increased 
healthcare costs [16]. However, little is known about how 
NCDs  truly  cluster  at  the  genetic,  molecular  or 
mechanistic levels, and there is scant understanding of 
Box 1: Priorities for the prevention and control of NCDs
May 2008: 61st World Health Assembly. WHO recommended 
a worldwide priority policy on NCD prevention and control 
(2008 to 2013), including cardiovascular disease, cancer, chronic 
respiratory diseases [101] and diabetes, not least because they 
often have common environmental risk factors [2].
May 2010: United Nations (UN) General Assembly unanimously 
adopted Resolution A/RES/64/265: ’Tackling NCDs constitutes 
one of the major challenges for sustainable development in the 
21st century‘ [102].
December 2010: the Council of the European Union adopted 
conclusions based on innovative and global approaches for 
NCDs in public health and healthcare systems to further develop 
population-based and patient-centered policies [1].
2010: US Center for Disease Control and Prevention (CDC) [103] 
says that ’an essential strategy for keeping older adults healthy is 
preventing NCDs and reducing associated complications’.
19 September 2011: UN General Assembly symposium on NCDs.
Figure 1. NCDs are associated with complex gene-environment interactions modulated by socio-economic determinants, psychological 
factors, age and gender. The products of these interactions lead to the biological expression of NCDs and further to their clinical expression with 
co-morbidities. A new definition of NCD phenotypes is needed to understand how a network of molecular and environmental factors can lead to 
complex clinical outcomes of NCDs for prevention and control.
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Page 2 of 12how specific combinations of NCDs influence prognosis 
and treatment [16].
NCDs are multi-factorial. In addition to environmental 
factors  and  increased  life  expectancy,  intrinsic  host 
responses,  such  as  local  and  systemic  inflammation, 
immune responses and remodeling [17], have key roles in 
the  initiation  and  persistence  of  diseases  and  co-
morbidities.  The  recent  increase  in  NCDs  has  been 
associated  in  part  with  biodiversity  loss  [18],  socio-
economic inequities linked with climate change, and loss 
of  natural  environments  [19].  A  more  comprehensive 
understanding  of  these  links  will  make  it  possible  to 
propose  more  effective  primary  prevention  strategies. 
The in utero environment is an important determinant of 
adult  NCDs,  including  diabetes  [20],  coronary  heart 
diseases  [21],  and  asthma  [22]  or  chronic  obstructive 
pulmonary disease (COPD) [23]. Mechanistic links have 
been proposed that involve fetal expression of genes that 
are  conserved  across  species,  epigenetic  mechanisms 
[22,24],  early  and  maternal  life  infections,  and/or 
environmental exposures. These need to be understood 
better [25], as early interventions may have the potential 
to reduce NCD burden [26].
Nutrition  is  a  key  determinant  of  health  and  NCDs. 
Understanding the underlying complexities of metabolic 
responses  and  pathophysiology  is  needed.  Loss  of 
biodiversity in food organisms causes micronutrient and 
vitamin deficiencies, and obesity and related chronic and 
degenerative  diseases  are  a  formidable  challenge  [27]. 
Nutritional  intervention  in  early  childhood  may  help 
prevent  autoimmune  diseases  [28],  and  adoption  and 
adherence to healthy diet recommendations are needed 
globally  to  prevent  the  onset  and  facilitate  control  of 
NCDs  [29].  However,  trying  to  change  lifestyles  using 
public health efforts remains a major challenge, and an 
interdisciplinary  social  and  behavioral  approach, 
including the cultural aspects of nutrition, is needed [30]. 
Tobacco  use  [31],  biomass  fuel  combustion  and  air 
pollution [32] are among the major risk factors for NCDs; 
these  act  as  early  as  in  utero  and  in  early  life.  Those 
working on the global prevention and control of NCDs 
should consider these risk factors because translational 
epidemiology  is  the  key  to  exploring  their  role  in  the 
development of NCDs and to devising approaches that 
will enable successful guided interventions [33].
The  development  of  a  society,  rich  or  poor,  can  be 
judged  by  the  health  of  its  population,  how  equitably 
health is distributed across the social spectrum, and the 
degree  of  protection  provided  to  people  who  are 
disadvantaged by illness. Effective action against NCDs 
needs  to  include  understanding  of  the  social  and 
economic determinants and their modification (Figure 1) 
[34].  Indeed,  best-practice  interventions  targeted  at 
coronary  risk  factors  eliminate  most  socioeconomic 
differences that affect coronary heart disease mortality, 
and this should serve as an example to follow for other 
NCDs  [35].  In  May  2009,  the  62nd  WHO  Assembly 
recommended  re-orienting  health  systems  globally  to 
promote  primary  healthcare  as  the  most  cost-effective 
strategy [36]. Healthcare often focuses on single diseases, 
advanced  technology,  biomedical  interventions  and 
specialist care. Most healthcare takes place in primary 
care settings [37], with emphasis on providing a complete 
range of care, from home to hospital, and on investing 
resources  rationally.  Fragmenting  care  can  reduce  the 
ability of primary care clinicians to ensure that patient 
care  is  comprehensive,  integrated,  holistic,  and 
coordinated [38], and to decide whether a person has a 
significant disease or temporary symptoms [39].
A proposal for multidisciplinary patient-centered 
management of chronic NCDs
We recommend that, to determine measures of disease 
severity and control, effective interventions and studies 
should  be  built  around  carefully  phenotyped  patients 
(Figure  2)  and  strictly  follow  carefully  crafted 
methodological standards. Patients should be placed at 
the  center  of  the  system;  if  they  are  aware  of  and 
understand  the  resulting  phenotype  data,  their  health 
will benefit. We stress that patients must understand that 
it is their societal responsibility to make their anonymized 
data available to appropriate scientists and physicians so 
that  the  latter  can  create  the  predictive  medicine  of   
the future that will transform the health of their children 
and grandchildren. For patients to adopt this approach,   
it  is  essential  that  laws  be  passed  protecting  them   
against  abuse  of  their  personal  data  by  insurance 
companies,  health  authorities  or  employers.  This 
approach to patient-centeredness, if aided by community 
health teams, will advance research. It may also benefit 
from the experience gained in patient-centered medical 
homes [40,41].
The concepts of severity, activity, control and response 
to treatment are linked. Severity is the loss of function in 
the target organs induced by disease and may vary over 
time;  as  it  may  also  vary  with  age,  this  needs  to  be 
regularly  re-evaluated.  Activity  is  the  current  level  of 
activation of biological pathways causing the disease and 
the clinical consequences of this activation. Control is the 
degree  to  which  therapeutic  goals  are  being  met  [42]. 
Responsiveness is the ease with which control is achieved 
by therapy [43]. Control can be achieved using clinical 
and/or biological end points, such as glycemic control in 
diabetes [44]. Careful monitoring of co-factors, such as 
compliance,  and  of  unavoidable  risk  factors  is  needed. 
The  uniform  definition  of  severe  asthma  presented  to 
WHO  is  based  on  this  approach  [45]  and  therefore 
provides a model to assess NCD severity (Figure 3).
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are needed for the implementation of integrated care in a 
systems medicine approach to enable prospective follow-
up  of  the  patients.  Home  telemonitoring  is  promising 
[46] and should be explored further because continuous 
and  precise  monitoring  makes  each  individual  clinical 
history a valuable source of comprehensive information. 
More  user-friendly  and  efficient  ICT  platforms  are 
needed that include shared decision making, the process 
by  which  a  healthcare  choice  is  made  jointly  by  the 
practitioner and the patient [47]. Ideally, an innovative 
patient  management  program  would  combine  ICT, 
shared  decision  making  and  personalized  education  of 
the  patient  (and  caregiver)  about  multidisciplinary 
approaches. The content, acceptance and effectiveness of 
such  approaches  should  be  tested  to  ensure  that  the 
autonomy,  quality  of  life  and  capacity  of  patients  are 
respected  and  enhanced,  and  that  their  values  and 
preferences  dominate  decision  making  [48].  Practice-
based  inter-professional  collaborations  is  also  key  to 
improving  healthcare  processes  and  outcomes  [49]. 
Qualitative  assessment  will  provide  insight  into  how 
interventions  affect  collaboration  and  how  improved 
collaboration contributes to changes in outcomes.
Thus, we propose that NCD management should move 
towards  holistic  multi-modal  integrated  care,  and 
Figure 2. Classical phenotypes are based on a priori ontologies (cardiovascular disease, chronic obstructive pulmonary disease (COPD) 
and type 2 diabetes), and new phenotypes are based on statistical modeling of all the complex components of NCD onset, persistence 
and prognosis.
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Page 4 of 12multi-scale,  multi-level  systems  approaches.  To  reduce 
their  socio-economic  and  public  health  impacts,  we 
propose  that  NCDs  should  be  considered  as  the 
expression of a continuum or common group of diseases 
with  intertwined  gene-environment,  socio-economic 
interactions  and  co-morbidities  that  lead  to  complex 
phenotypes  specific  for  each  individual.  The  ‘systems 
medicine’ concept, which takes a holistic view of health 
and  disease,  encapsulates  this  perspective.  Systems 
medicine aims to tackle all components of the complexity 
of NCDs so as to understand these various phenotypes 
and  hence  enable  prevention  (Box  2),  control  through 
health promotion [50] and personalized medicine [51], 
and an efficient use of health service resources [52]. It 
does this through integrated care using multidisciplinary 
and  teamwork  approaches  centered  in  primary  and 
community  care  [53],  including  the  essential  ethical 
dimension.
Systems biology and medical informatics for P4 
medicine of chronic NCDs
The main challenge regarding NCDs in the 21st century 
is to understand their complexity. Biology and medicine 
may be viewed as informational sciences requiring global 
systems  methods  using  both  hypothesis-driven  and 
discovery-driven  approaches.  Systems  medicine  is  the 
application of systems biology to medical research and 
practice [54,55]. Its objective is to integrate a variety of 
data  at  all  relevant  levels  of  cellular  organization  with 
clinical and patient-reported disease markers. It uses the 
power of computational and mathematical modeling to 
enable  understanding  of  the  mechanisms,  prognosis, 
diagnosis  and  treatment  of  disease  [56].  It  involves  a 
transition  to  predictive,  preventive,  personalized  and 
participatory (P4) medicine, which is a shift from reactive 
to prospective medicine that extends far beyond what is 
usually  covered  by  the  term  personalized  medicine 
Figure 3. The concept of a uniform definition for NCD severity is based on control, responsiveness to treatment and risks (short, medium 
and long term). A single flow chart is proposed to define severity to improve phenotype characterization for all purposes (research, clinical and 
public health). It is based on diagnosis, therapeutic interventions and their availability/affordability, risk factors and co-morbidities.
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Page 5 of 12[57,58].  It  incorporates  patient  and  population 
preferences  for  interventions  and  health  states  by 
implementing  effective  societal  actions  [57]  with  an 
important public health dimension [59]. It is likely to be 
the foundation of global health in the future (Box 3).
Thus,  there  is  an  urgent  need  for  development  of 
information management systems that can enable secure 
storage  of  heterogeneous  data,  including  clinical  data, 
and  provide  tools  for  the  management,  search  and 
sharing of the data. Such information needs to accessible, 
shared between investigators, queried, and integrated in 
a controlled and secure manner with molecular profiles 
and images obtained from high-throughput facilities. For 
example, one prediction arising from considerations of 
the evolution of P4 medicine suggests that, in 10 years or 
so, each patient will be surrounded by a virtual cloud of 
billions  of  data  points;  we  will  need  information 
technology to reduce this staggering data dimensionality 
to simple hypotheses about health and disease for each 
individual patient [57].
A  systems  biology  approach  that  is  unbiased  by  old 
classification systems can be used to find new biomarkers 
of  co-morbidities,  disease  severity  and  progression.  In 
this approach, phenotypes of NCDs are analyzed in an 
integrative  manner  using  mathematical  and  statistical 
modeling,  taking  all  diseases  into  account,  and 
embedding co-morbidities, severity and follow-up of the 
patients through analyses in dynamic models (Figure 4). 
Unknown phenotypes are defined and further analyzed 
using  iterative  cycles  of  modeling  and  experimental 
testing.  Novel  biomarkers  are  identified  combining 
datasets  from  genomics,  epigenetics,  proteomics, 
transcriptomics,  metabolomics  and  metagenomics. 
These new complex biomarkers will need to be validated 
and  replicated  in  independent  controls  or  prospective 
patient cohorts [60]. Using methods used in non-medical 
complex model systems, it should be possible to monitor 
‘early warning signals’, which predict the state of disease 
progression,  and  the  occurrence  of  abrupt  phase 
transitions  (slowing  down,  increase  in  autocorrelation 
and  variance)  [61].  For  example,  in  a  mouse  model  of 
neurodegenerative disease, blood biomarkers have been 
shown to allow pre-symptomatic diagnosis and analysis 
of the stage of disease progression [62].
Modeling is a powerful tool for reducing the enormous 
complexity  of  comprehensive  biological  datasets  to 
simple hypotheses. Modeling of the temporal behavior of 
disease read-outs at short [63] or long [64] intervals can 
identify sub-phenotypes of NCDs. Attempts to find novel 
biomarkers  of  disease  development  using  a  systems 
biology  approach  have  been  used  to  assess  the 
mechanisms of severe asthma, allergy development [65] 
and cancer. One important role that biomarkers will have 
is to stratify a given disease into its different subtypes so 
that appropriate and distinct therapies can be selected for 
each  subtype.  Phenotypes  can  be  modeled  using 
statistical  approaches,  such  as  scale-free  networks  and 
Bayesian  clustering  models,  that  are  based  on  the 
evaluation of NCDs as a whole, taking into account co-
morbidities, severity and follow-up. This approach will 
Box 2: Glossary of terms
The classical definition of prevention [101] includes:
•  Primary prevention: to avoid the development of disease.
•  Secondary prevention: recognize a disease before it results 
in morbidity (or co-morbidity).
•  Tertiary prevention: to reduce the negative impact of 
established disease by restoring function and reducing 
disease-related complications.
Expanding on the traditional model of prevention, Gordon [104] 
proposed a three-tiered preventative intervention classification 
system on the basis of the population for whom the measure is 
advisable based on a cost-benefit analysis:
•  Universal prevention addresses the entire population (for 
example, national, local community, school, and district) and 
aims to prevent or delay risk factor exposure. All individuals, 
without screening, are provided with information and skills 
necessary to prevent the problem.
•  Selective prevention focuses on groups whose risk of 
developing problems is above average. The subgroups may 
be distinguished by characteristics such as age, gender, family 
history, or economic status.
•  Indicated prevention involves a screening process.
According to these definitions, health promotion [50] should 
be used for primary universal and selective prevention strategies, 
whereas P4 medicine (predictive, preventive, personalized and 
participatory) [51] should be used for primary, secondary and 
tertiary indicated prevention strategies.
Box 3: Key expected benefits of P4 medicine
To prevent the occurrence of NCDs by implementing effective 
action at societal and individual levels:
•  To detect and diagnose disease at an early stage, when it can 
be controlled effectively.
•  To stratify patients into groups, enabling the selection of 
optimal therapy.
•  To reduce adverse drug reactions through the predictive or 
early assessment of individual drug responses and assessing 
genes leading to ineffective drug metabolism.
•  To improve the selection of new biochemical targets for drug 
discovery.
•  To reduce the time, cost, and failure rate of clinical trials for 
new therapies.
•  To shift the emphasis in medicine from reaction to prevention 
and from disease to wellness.
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patient-specific  phenotypes.  The  challenge  will  be  to 
develop  efficient,  automated  and  integrated  workflows 
that  predict  the  most  suitable  therapeutic  strategy  not 
only at the population level but, most importantly, at the 
individual patient level.
Bioinformatics, medical informatics and their interplay 
(sometimes termed biomedical informatics) will be key 
enablers  in  structuring,  integrating  and  providing 
appropriate access to the enormous amount of relevant 
data and knowledge [66,67]. Medical informatics needs 
to provide ubiquitous and powerful electronic healthcare 
record  technologies  to  securely  aggregate  and  handle 
diverse,  complex,  and  comprehensive  data  types  [68]. 
Biomedical informatics must develop ways to use these 
content-rich  electronic  healthcare  records  to  provide 
advanced decision support that considers all aspects of 
normal and disease biology, guided by clinically relevant 
insights  and  biomarker  discovery  research  strategies 
[69,70]. Bioinformatics will need to constantly restructure 
and  refine  global  data  to  distill  the  clinically  useful 
elements and the derived models, so they can feed this 
information  system  in  a  real-time,  automated  fashion, 
constantly incorporating clinical expertise. P4 medicine 
is  evolving  so  rapidly  in  its  understanding  of  disease 
states that the individual patient’s data must continually 
be re-examined so that new insights into the health and 
disease state of the individual can be gained. This general 
informatics  framework,  based  on  an  advanced  ICT 
infrastructure, will provide the basis for empowering P4 
medicine.
Given the complexity of NCDs, bio-clinical scientific 
progress  will  depend  critically  on  large-scale  pooled 
analyses of high quality data from many biobanks [71] 
and  bio-clinical  studies  (such  as  BioSHaRE-EU  [72]). 
Biomedical  informatics  and  knowledge  management 
platforms  have  made  significant  advances  towards 
enabling  the  development  of  technologies  to  organize 
molecular data at the level required for the complexity of 
NCD  data  [73,74].  Data  analysis,  integration  and 
modeling require strict statistical procedures in order to 
avoid false discoveries [75]. They can be performed, for 
example,  using  the  joint  knowledge  management 
platform of European Framework Program 7 (EU FP7) 
projects,  including  U-BIOPRED  [76],  MeDALL  [65], 
AirPROM  and  SYNERGY-COPD,  and  using  similar 
initiatives  worldwide.  Large-scale  profiling  to  discover 
early  markers  of  disease  progression  before  the 
appearance of any symptoms has already been performed 
in a large prospective human cohort [77,78].
Complementary  approaches  using  computational 
models  that  extend  existing  models  derived  from  the 
Physiome project, including biomedical imaging, can be 
used together with statistical modeling of various types 
of clinical data to further define phenotypes and develop 
predictive  models.  These  can  be  used  within  the 
framework of a fully integrated (preferably open source) 
knowledge management platform [79]. Such a platform 
for  knowledge  management,  including  annotation  and 
ontologies,  would  then  operate  on  top  of  the  medical 
informatics infrastructure, setting the stage for a systems 
medicine approach to NCDs. In our collective experience 
these  necessary  aspects  of  medical  informatics  have  a 
tendency to be overlooked in funding efforts targeting 
complex diseases.
Integrated care of chronic NCDs using P4 systems 
medicine
Integrated care, a core component of health and social 
care reforms, seeks to close the traditional gap between 
health  and  social  care  [80].  Population  health  sciences 
should integrate personalized medicine in public health 
interventions  to  prevent  and  manage  NCDs  in  a  cost-
effective manner by involving all stakeholders, including 
patients [81]. The objectives of this proposed integration 
Figure 4. Iterative mathematical modeling to increase 
knowledge on NCDs. Various targeted or comprehensive data 
types are collected from samples of individuals with carefully 
defined phenotypes, processed using probabilistic and network 
analysis tools, and integrated into predictive models using a 
knowledge management and simulation platform, leading to the 
refinement of the classification of NCDs. Mechanistic hypotheses 
and complex biomarkers of NCDs generated through this process 
are then tested and validated iteratively using small then large 
cohorts of independent samples, providing potential diagnostic and 
therapeutic solutions for the general population.
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clustering/
network analysis
Data types
Validation/
model
iteration
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Page 7 of 12are: (i) to investigate questions related to NCDs; (ii) to 
improve the quality of primary care; and (iii) to widely 
disseminate  new  information  that  will  improve  overall 
health  at  both  a  local  and  national  level  [82]. Chronic 
diseases  can  disconnect  individuals  from  their  usual 
milieu, with negative implications for physical, social and 
mental  well-being.  Moving  beyond  the  disease-by-
disease approach to tackle NCDs demands an improved 
understanding  of  NCD  by  patients,  and  a  better 
understanding  of  their  common  causes.  At  the  local   
level, strategies such as community oriented primary care 
can  link  and  reinforce  personal  and  public  health 
efforts [83].
To  understand,  preserve  and  improve  the  health  of 
human  populations  and  individuals,  an  integrated 
research  strategy  should  include  all  components  of 
research on NCDs and be integrated for optimal patient 
management [84,85]. Careful evaluation is needed of: (i) 
the  acceptance  of  multi-morbidity  of  NCDs  by  the 
patient, with particular attention to cultural and social 
barriers, gender and age; (ii) the engagement of patients 
in  decisions  regarding  management  [86],  research  and 
clinical trials [55,57]; and (iii) the improvement of quality 
of life that would result from the proposed management. 
Targeting  NCDs  and  their  comorbidities  will  directly 
affect  healthy  aging,  which  has  been  described  as  a 
‘keystone for a sustainable Europe’ [87]. Screening, early 
diagnosis,  prevention  and  treatment  of  hidden 
comorbidities  in  patients  with  diagnosed  NCDs  will 
reduce their morbidity and increase healthy life years.
The direct and indirect costs of uncontrolled NCDs are 
substantial  for  the  patient,  the  family  and  society, 
especially in underserved populations [9]. P4 medicine 
should be put into the context of health economics to 
show that expensive strategies are cost-effective [55,57]. 
Chronic diseases place a considerable economic burden 
on  the  society  and  increase  inequities.  The  social 
dimension of NCDs needs to be pursued in the economic 
and  employment  fields.  The  net  social  benefit  of 
improving  medical  and  social  care  related  to  NCDs 
should  take  co-benefits  into  account.  Health  costs  for 
NCDs should be balanced with health benefits, wealth 
creation and economic development. The management 
of NCDs requires the coordination of stakeholders in the 
public  and  private  sectors  within  a  governance 
framework  that  includes  networks  of  care.  Therefore, 
research should be done to identify social determinants 
and to create public health systems that translate efficacy 
into  effectiveness  in  the  community  [88].  Moreover, 
strengthening  health  equity  across  nations  and 
socioeconomic groups is needed to meet the ambitions 
of  the  Commission  on  Social  Determinants  of  Health, 
who  have  proposed  closing  the  health  gap  between 
nations and groups in a generation [89].
Values are the basis of most actions in health and the 
economy, and these values are often not made explicit. 
Changing  paradigms  and  approaches  to  NCDs  may 
challenge  fundamental  societal  values  and  professional 
habits [59,90]. The apparent contradiction between the 
development  of  a  more  tailored  medical  approach  to 
NCDs  and  the  public  health  dimensions  of  their 
prevention and care needs to be addressed using a value-
based  analysis.  Thus,  a  thorough  analysis  of  values 
underlying P4 medicine should be conducted in diverse 
contexts and should become part of the basis of decision-
making.  The  respective  weight  of  the  multiple 
stakeholders  involved  in  the  priority  setting  must  be 
made clear, with transparency and proportionality as key 
features.  P4  medicine  development  should  be  a  global 
aim  and  not  a  privilege  of  ‘rich’  countries.  Using  data 
obtained from all components of research, guidelines on 
NCDs  applicable  to  primary  care  could  be  developed 
using  up-to-date  methodology  [91,92].  Policies  for 
implementation could then be proposed, to translate the 
concept of NCD into practice. They should distribute the 
burdens equitably, also considering gender and age.
Multidisciplinary  training  of  all  stakeholders,  with 
particular  emphasis  on  the  participation  of  patient 
associations,  is  a  further  essential  component.  Many 
health and non-health professionals need to be educated 
in the general approach to the research and management 
of  patients  with  NCDs.  Innovative  training  programs 
using ICT will be essential in this implementation. Such 
education will also need to address questions of how to 
teach the subject and how people learn it, rather than 
merely regarding education as a process of transmission 
and  transaction  for  everyone  involved.  This  includes 
taking into account points of view, habits of mind, and all 
the information requested for the needs of the strategy. 
The  educational  program  needs  to  forge  educational 
systems  to  help  participants  think  in  a  coherent  way 
about  NCDs.  A  module  of  the  program  should  be 
developed  around  patient  feedback  to  help  them  be 
engaged in all aspects of NCDs, including research.
Many patients with NCDs live in developing countries 
where medications and services are often unavailable or 
inaccessible.  Effective  medications,  such  as  inhaled 
corticosteroids  for  asthma  [93]  or  insulin  for  diabetes, 
should be made available for all patients [94]. In addition, 
there should be a global cost-effective application of P4 
medicine across the world [95]. It is likely that genomic 
applications  and  ICT  will  become  available  to  many 
developing countries at a relatively low cost in the next 
few  years.  In  addition,  new  private-public  strategic 
partnerships,  such  as  the  pre-competitive  Innovative 
Medicines Initiative, a joint undertaking of the European 
Union and the European Federation of Pharmaceutical 
Industry  Associations  [96],  and  the  Program  on 
Bousquet et al. Genome Medicine 2011, 3:43 
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Page 8 of 12Public-Private Partnerships of the United States National 
Institutes  of  Health  Roadmap  [97],  are  required  to 
overcome  the  bottlenecks  in  the  development  of  new 
treatment  strategies  [98].  WHO  actively  supports 
capacity  building,  especially  in  developing  countries, 
fosters  partnerships  around  the  world,  and  works  to 
narrow the gap in healthcare inequities through access to 
innovative  approaches  that  take  into  account  different 
health  systems,  economic  and  cultural  factors.  Despite 
the  growing  consensus  for  the  need  for  health  system 
strengthening, there is little agreement on strategies for 
its implementation [99]. Widely accepted guiding principles 
should  be  developed  with  a  common  language  for 
strategy development and communication for the global 
community in general [100] and for NCDs in particular.
Conclusions
NCD  management  needs  to  move  towards  integrated 
care,  global  strategies  and  multi-modal  systems 
approaches, which will reduce the burden and societal 
impact  of  NCDs.  To  this  end,  we  propose  that  NCDs 
must be considered as the expression of a common group 
of  diseases  with  different  risk  factors,  socio-economic 
determinants  and  co-morbidities.  This  will  enable  the 
application of P4 medicine principles to NCDs, exploiting 
their commonalities, bringing improved global healthcare 
and the reduction of inequities around the world. The 
expected results targeted to better support for patients 
include:  (i)  better  structuring  of  translational  research 
and  development  for  NCDs;  (ii)  greatly  enhanced 
prevention  and  treatment  capabilities;  (iii)  innovative 
healthcare  systems  with  implementation  of  follow-up 
procedures directly in the homes of patients; (iv) slowing 
down  of  health  expenditure  increase;  and  (v)  new 
interdisciplinary training curricula.
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